Sapan Gai, CCO at Sovereign Metals, discusses their superior graphite test results. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFrontier Ip Regulatory News (FIPP)

Share Price Information for Frontier Ip (FIPP)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 41.00
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 2.00 (5.00%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 41.00
FIPP Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Frontier IP to host Portfolio Demo Day

6 Dec 2022 07:00

RNS Number : 6710I
Frontier IP Group plc
06 December 2022
 

Reach - a non-regulatory announcement

AIM: FIPP

06 December 2022

 

Frontier IP Group Plc

("Frontier IP" or the "Group")

 

 

Portfolio news - Frontier IP to host Portfolio Demo Day at the Imperial War Museum, Duxford Cambridge

 

 

Frontier IP, a specialist in commercialising intellectual property, is holding a Portfolio Demo Day at the Imperial War Museum, Duxford, Cambridge ("IWM Duxford" or the "Museum") on the afternoon and evening of Tuesday 6th December 2022.

 

The event is an opportunity for some of Frontier IP's portfolio companies to present, demonstrate and discuss their new technologies to help tackle fundamental challenges, such as climate, energy, food, water and health.

 

Guests include investors, representatives of companies supported by Frontier IP, and industry partners. An afternoon session in the Museum's Marshall Auditorium will consist of presentations from portfolio companies, while the evening reception will give them the opportunity to showcase their technology. No new material information will be disclosed.

 

The portfolio companies presenting and demonstrating technologies are:

 

· Cambridge Raman Imaging is using graphene-based ultra-fast lasers and artificial intelligence in next generation Raman-imaging microscopes to research, diagnose and monitor diseases, such as cancers

 

· CamGraPhIC is developing graphene-based photonics with the potential to make data and telecommunications transmission much faster while using less energy

 

· Elute is showcasing its use of forensic linguistic algorithms for high-speed search and comparison of unstructured document datasets

 

· Celerum is demonstrating its novel artificial intelligence based on meta-heuristics, including nature-inspired computing, to make logistics more efficient, supporting efforts to improve the industry's carbon efficiency

 

· Nandi Proteins is discussing its customised ingredients based on vegetable and animal proteins. These can be used to replace undesirable ingredients such as fat, gluten and E-number additives in processed foods, or those that people do not want to consume - for example replacing animal proteins with vegetable proteins

 

· The Vaccine Group is developing novel herpesvirus-based vaccine platforms. Projects include those to tackle Lassa fever, African Swine Fever, Streptococcus suis and Porcine Reproductive and Respiratory Syndrome in animals, and COVID-19 in humans

 

· Pulsiv will be showing its patented technology to significantly improve the energy efficiency of power supplies, battery chargers, and LED lighting. It also extracts much more energy from photovoltaic solar cells, improving their output

 

· Alusid is creating premium-quality tiles and architectural surfaces from industrial waste.

 

· Des Solutio is developing safer and greener alternatives to the chemicals currently used to make beauty, pharmaceutical, personal healthcare and other products

 

· InSignals Neurotech is showing its patented technology to aid deep brain surgery on patients suffering neurological diseases, such as Parkinson's disease

 

· AquaInSilico is presenting its sophisticated software tools to optimise wastewater treatment, with potential applications spanning many different industries. It is a UN Ocean Innovator, working on a project to help protect and conserve one of the world's most diverse marine environments around the Cape Verde archipelago

 

· Liquid Graphene is a new spin-out company looking to exploit graphene-based inks to reduce the cost of solar cell manufacture and use

 

 

Frontier IP Chief Executive Officer Neil Crabb said: "We are looking forward to demonstrating the exciting technologies being developed by our portfolio companies and the role they have to play in helping to meet some of the serious challenges posed by climate change, water, food and energy."

 

 

 

 

 

 

ENQUIRIES

 

 

Frontier IP Group Plc

T: 020 7332 2338

Neil Crabb, Chief Executive Officer

Andrew Johnson, Communications and investor relations

andrew.johnson@frontierip.co.uk

Company website: www.frontierip.co.uk

neil@frontierip.co.uk

M: 07464 546 025

 

 

Allenby Capital Limited (Nominated Adviser)

Nick Athanas / George Payne

 

 

 

T: 0203 328 5656

 

 

 

 

 

ABOUT FRONTIER IP

Frontier IP unites science and commerce by identifying strong intellectual property and accelerating its development through a range of commercialisation services. A critical part of the Group's work is involving relevant industry partners at an early stage of development to ensure technology meets real world demands and needs.

The Group looks to build and grow a portfolio of equity stakes and licence income by taking an active involvement in spin-out companies, including support for fund raising and collaboration with relevant industry partners at an early stage of development.

About Reach announcements

 

This is a Reach announcement. Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases into the public domain. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on Reach.

 

 

 

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAVELFBLLLXFBB
Date   Source Headline
6th Dec 20196:25 pmRNSHolding(s) in Company
5th Dec 201912:00 pmRNSHolding(s) in Company
4th Dec 201912:00 pmRNSResult of AGM & Total Voting Rights
26th Nov 201912:58 pmRNSHolding(s) in Company
13th Nov 20195:00 pmRNSPosting of Annual Report and Accounts
7th Nov 201912:20 pmRNSHolding(s) in Company
6th Nov 20192:00 pmRNSResult of Placing
6th Nov 20197:01 amRNSProposed fundraising of £3.5m by way of Placing
6th Nov 20197:00 amRNSFinal Results
22nd Oct 20197:00 amRNSAppointment of senior advisers
15th Oct 20197:00 amRNSNew portfolio company: Elute Intelligence Holdings
10th Sep 20197:00 amRNSAppointment of Broker
25th Jul 20197:00 amRNSExscientia collaboration with Rallybio
15th Jul 201912:08 pmRNSHolding(s) in Company
14th Jun 20197:00 amRNSExscientia partnership with GT Apeiron
31st May 20195:00 pmRNSTotal Voting Rights
31st May 20193:15 pmRNSDirectorate Change
28th May 20197:00 amRNSFieldwork Robotics completes initial field trials
15th May 20197:00 amRNSDirector exercise of options, shareholding and TVR
10th May 201911:48 amRNSHolding(s) in Company
30th Apr 20197:00 amRNSEuropean plan to boost marine & coastal economies
8th Apr 20197:00 amRNSParkside Architectural Tiles launch Alusid range
8th Apr 20197:00 amRNSBosch UK to work with Pulsiv Solar
8th Apr 20197:00 amRNSInvestor event at the Royal Academy of Engineering
4th Apr 20197:00 amRNSExscientia reaches first major milestone with GSK
3rd Apr 20195:51 pmRNSHolding(s) in Company
3rd Apr 20193:45 pmRNSHolding(s) in Company
1st Apr 20197:00 amRNSFieldwork Robotics wins Innovate UK ISCF grant
27th Mar 20191:30 pmRNSHolding(s) in Company
27th Mar 20191:30 pmRNSHolding(s) in Company
27th Mar 20197:00 amRNSBoard Appointment
27th Mar 20197:00 amRNSUnaudited Half Year Results
21st Mar 20199:18 amRNSTrading Update
21st Mar 20199:14 amRNSExscientia & Celgene drug discovery collaboration
6th Mar 20195:15 pmRNSHolding(s) in Company
20th Feb 20197:00 amRNSTVG - key partner in $9.67m DARPA project award
12th Feb 20197:00 amRNSThird Portuguese spin out: Insignals Neurotech
4th Feb 20197:00 amRNSAmprologix wins DHSC backing for new antibiotic
31st Jan 20199:00 amRNSNandi Proteins led consortium wins UK grant
25th Jan 20197:00 amRNSThe Vaccine Group wins Department of Health grant
7th Jan 20191:29 pmRNSExscientia Series B funding & Roche collaboration
27th Dec 20187:00 amRNSMolendotech - Palintest start commercial roll out
19th Dec 201811:45 amRNSResult of AGM
30th Nov 20185:30 pmRNSTotal Voting Rights
23rd Nov 201812:10 pmRNSPosting of Annual Report and Notice of AGM
22nd Nov 20181:12 pmRNSHolding(s) in Company
22nd Nov 201810:36 amRNSHolding(s) in Company
21st Nov 20183:30 pmRNSHolding(s) in Company
21st Nov 201811:00 amRNSTotal Voting Rights and Director/PDMR Shareholding
15th Nov 20184:08 pmRNSDirector Dealing

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.